The Pharmaceutical Research and Manufacturers of America (PhRMA) has released a report showing that U.S. biopharmaceutical companies have more than 240 medicines in development for the treatment of leukemia, lymphoma and multiple myeloma. The report provides details on each of the medicines, including sponsor, indication and development phase. Noting that more than 100,000 new cases of blood, bone marrow and lymph node cancers are diagnosed in the United States annually, PhRMA points to the “significant progress in biopharmaceutical research and development” that has achieved “steady improvements in cancer survivorship rates.” See PhRMA News Release, April 25, 2013.